Molecular-Targeted Therapy For Malignant Mesothelioma
نویسندگان
چکیده
منابع مشابه
Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.
Despite the use of aggressive trimodality therapy consisting of neoadjuvant chemotherapy, surgery, and hemithoracic radiation, the median survival of patients with malignant pleural mesothelioma (MPM) is 12 to 18 months (1,2). Immune responses have been shown to be beneficial in MPM patients (3,4); therefore, focusing immunotherapeutic strategies on promoting these immune responses is an attrac...
متن کاملPRIMARY MALIGNANT PERICARDIAL MESOTHELIOMA
Primary malignant neoplasms of the pericardium are rare and are predominantly mesotheliomas, followed by benign localized fibrous mesothelioma, malignant fibrosarcoma, angiosarcoma and benign and malignant teratomas. 1 This article concerns an atypical presentation of this malignant tumor with symptoms and signs of pericardial effusion. This unusual feature was complete encasement of the h...
متن کاملCombining molecular targeted agents with radiation therapy for malignant gliomas
The expansion in understanding the molecular biology that characterizes cancer cells has led to the rapid development of new agents to target important molecular pathways associated with aberrant activation or suppression of cellular signal transduction pathways involved in gliomagenesis, including epidermal growth factor receptor, vascular endothelial growth factor receptor, mammalian target o...
متن کاملMultimodality therapy for malignant pleural mesothelioma.
Mesothelioma is a rare disease for which neither single modality nor bimodality therapy improves survival. For this reason, from 1980 to 1995, we used trimodality therapy in an attempt to improve survival in selected patients at Brigham and Women's Hospital and Dana-Farber Cancer Institute. One hundred twenty patients underwent trimodality treatment involving extrapleural pneumonectomy followed...
متن کاملGene therapy for malignant pleural mesothelioma.
Malignant mesothelioma (MM) is a fatal malignancy refractory to all forms of standard anticancer therapy. This article reports the results of a phase I clinical trial assessing the safety of intrapleural delivery and efficacy of intratumoral gene transfer of recombinant adenovirus (rAd) containing herpes simplex virus thymidine kinase (HSVtk) gene into the pleural space of patients with MM, fol...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLEURA
سال: 2015
ISSN: 2373-9975,2373-9975
DOI: 10.1177/2373997515600403